WO1999053934A1 - Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis - Google Patents
Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis Download PDFInfo
- Publication number
- WO1999053934A1 WO1999053934A1 PCT/DK1999/000212 DK9900212W WO9953934A1 WO 1999053934 A1 WO1999053934 A1 WO 1999053934A1 DK 9900212 W DK9900212 W DK 9900212W WO 9953934 A1 WO9953934 A1 WO 9953934A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rose
- formulation
- hip
- powder
- arthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of dried rose-hip for the preparation of formulations for the treatment or prophylaxis of a number of conditions associated with inflammation including arthritis.
- the invention also relates to methods of preparing these formulations.
- RA rheumatoid arthritis
- TNF ⁇ tumor necrosis alpha
- IL- 1 interleukine-l
- IL-6 interleukine-6
- Incidence of arthritis appears to be approximately the same in most populations throughout the world, about 1% of adult females and 0.5% of adult males. Some pockets of higher incidence has been observed in certain parts of the world. However, the role of sex appears to be stronger than any geographical or racial factors as a disease determinant. It is claimed that in the Western World approximately 70% of the population over the age of 70 have symptoms of osteoarthritis.
- MHC-II major histocompatibility complex
- Environmental factors such as stress, viruses such as Epstein-Barr virus and parvo virus and collagen as an auto immunogen have also been mentioned as factors related to the development of arthritis.
- the disease appears to be initiated by the activation of T-cells.
- Inflammatory cytokines such as TNF- ⁇ are involved in the amplification of the disease process.
- Proliferation of endothelial cells in the rheumatoid synovium is an important component of inflammation in arthritis.
- the actual tissue damage is caused by the inflammatory cells such as PMNs and mono- cytes/macrophages. The damage is caused by the release of proteolytic and hydrolytic enzymes as well as toxic reactive oxygen radicals from these cells activated in the tissue and joints.
- Treatment for arthritis involves alleviation of the symptoms associated with the disease, such as relief of pain, reduction of inflammation and increase of motion.
- Acetyisalicylic acid such as Aspirin
- nonsteroid anti-inflammatory drugs such as ibuprofen, methotrexate and naproxen
- glucocorticoid have been used for the treatment of arthritis. Control of the symptoms with these drugs requires long term daily treatment.
- These drugs have a variety of toxic and other side effects, such as gastric erosion and adverse effects on kidneys and liver. Some of these drugs particularly glucocorticoid, inhibit the immune response to infections. Therefore, there is a great need for alternative therapies for the management of arthritis which can eliminate the need for traditional drugs and their side effects particularly for prolonged daily use.
- a formulation comprising a rose-hip concentrate containing a high vitamin content relative to conventionally dried rose-hip.
- the rose-hip concentrate comprises ground and dried rose-hip, the rose-hip dried at temperatures below 50°C, and in darkness to maintain the high vitamin content.
- the rose-hip is formulated for oral administration, preferably in tablet or capsule form. One or multiple dose of the formulation may be administered totalling from about 20-200g per day.
- the inventors have discovered an anti-inflammatory property of rose-hip formulations, and that the use of the formulations, in a prophylactic and/or therapeutic regiment, prevents or alleviates and reduces symptoms associated with arthritis, such as rheumatoid arthritis, osteoarthritis, reactive arthritis and other forms of inflammation.
- Daily intake of rose-hip as described in this invention can replace or supplement conventional drug therapies and improve the quality of life in patients suffering from arthritis by relieving pain and improving motion in these patients.
- Figure 1 is a graph showing the uptake of vitamin C present in rose-hip powder administered to healthy volunteers.
- An amount of rose-hip powder having an equivalent of 250 mg of vitamin C present in about 45 g of rosehip powder was administered by oral intake to healthy volunteers and the blood level of vitamin C was measured at different time points. The powder was swallowed and washed down with water. 500 mg of commercially available vitamin C in tablet form was administered to control subjects.
- Figure 2 is a graph showing the blood levels of C-reactive protein (CRP) in individuals before (day 0), during (day 10 and day 28) and after treatment (day 62) with 45 grams daily intake of rose-hip for 28 days. The results are given as mean values and in mg/L CRP.
- CRP C-reactive protein
- Figure 3 is a graph showing the chemotaxis of peripheral blood polymorphonuclear leucocytes from subjects during and 28 days after cessation of treatment with 45 grams daily intake of rose-hip for 28 days.
- the chemotaxis is determined towards the chemotactic peptide fMLP.
- the results are given as mean number of cells migrated from 17 subjects.
- Figure 4 is a graph showing the chemotaxis of peripheral blood polymorphonuclear leucocytes from subjects during and 28 days after cessation of treatment with 45 grams daily intake of rose-hip for 28 days.
- the chemotaxis is determined towards zymosan activated serum (ZAS).
- ZAS zymosan activated serum
- the present invention is directed to a formulation using rose-hip concentrate containing a high vitamin content.
- Rose-hip is harvested in a generally known manner when the hips are fully ripe. Hips from wild rose bushes, notably rosa canina, rosa gallica, rosa condita and rosa rugosa, may be used, but the hips of the rosa canina are particularly well suited to use in the invention.
- the hips are harvested, they are chopped into pieces. If further processing is delayed, the hips may be frozen for storage.
- the next step is to dry the chopped rose-hips to a water content of about 5% by weight. It is essential that the drying be conducted in a manner which preserves the vitamin content of the rose-hips. Preferably, drying is conducted at a temperature below 50°C with air and avoiding sunlight.
- a powder has a high content of vitamin B, E and C, with about 560 mg vitamin C per 100g powder. It may be beneficial to utilize low pressure as well as low temperature to facilitate drying. Above 50°C, notable deterioration in vitamin content is possible.
- the dried, chopped rose-hips then pass through a separation step to remove nuts, hairs, and other extraneous matter that may have accompanied the rose-hips during harvesting.
- the remaining fruit flesh is then crushed in a grinding mill.
- a powder or granular material may be obtained having a particle size of below 1 mm, with about 0.1 to 0.5 mm preferred.
- the term "powder” will be used to cover the full spectrum of the dried rose-hips in whatever solid form it takes.
- the powder may be referred to herein on occasion as "a concentrate” or as "an extract” and it will be understood, of course, that the powder may be presented and used as a solution, suspension or emulsion, and the invention is not limited to the solid form.
- the powder may be packed in a conventional manner in bags, pelletized or placed directly into capsules with a physiologically acceptable carrier for formulation into unit dosages.
- a physiologically acceptable carrier for formulation into unit dosages.
- An advantage of the rose-hip powder is that it may, without special processing, be incorporated into foods or beverages such as baked goods, non-baked goods, fruit and other beverages, etc. as well as be formulated with other dietary supplements such as vitamins, minerals, and other materials which may offer complimentary beneficial effects, such as anti-oxidants. This substantially simplifies the ability of a person suffering from inflammation including arthritis to obtain and maintain the amount necessary for the daily intake of the rose-hip powder to obtain beneficial results.
- a unit dosage can comprise a therapeutically effective amount of the rosehip powder for a single daily administration (e.g., orally or by feeding tube in an enteral diet); or it can be formulated into smaller quantities to provide for multiple doses in a day.
- the formulation of this invention can be manufactured into tablets, capsules, caplets, elixirs, enteral formulations or incorporated into slow releasing carriers.
- physiologically acceptable vehicles including water, oil emulsions, alcohol or any of the food/beverage formulations described herein.
- a unit dosage as stated above, will depend upon many factors including age, condition and disease state of the patient and the number of times the unit will be taken in a single day. In any event, the entire daily dosage will be that which is physiologically acceptable to an individual and can be administered daily over a prolonged period of time. 8
- a preferred unit dosage of the inventive powder will be from about 0.25 to about 2.0g/kg/day. Thus, the total amount will likely be from about 20 to about 200g/day, with about 40-120g/day preferred.
- the formulations can be incorporated within or used on many of the foods and beverages one can consume on a daily basis.
- suitable foods and beverages which could be made, include but are not limited to, nutritional beverages, soft drinks, fruit beverages and juices, electrolyte containing beverages, puddings, baked goods (i.e., cookies, brownies, fudge, cake, breads), non-baked extruded foods (i.e., bars), salad dressings, condiments, confections (i.e., candy), snack foods (i.e., chips, pretzels, tortillas), drips and spreads, ice cream, frozen confections and novelties, dairy products such as yoghurt, margarine-like spreads, seasonings such as for meat, poultry, seafood and salads.
- Fat free, reduced fat and low calorie versions of these foods are embraced by this invention.
- Incorporation of the formulation into foods/beverages provides the advantages of patient compliance over a prolonged period of use and in a form which is more desirable to the consumer, rather than in the form of a medicament.
- the powder of the invention has various vitamins and minerals as determined according to conventional methods. These are shown in the following Table 1.
- Vitamin A ⁇ 10 ⁇ g/100g
- Vitamin B1 ⁇ 0.2 mg/100g
- Vitamin B2 0.99 mg/100g
- Vitamin B6 0.20 mg/100g Vitamin B12 ⁇ 0.5 ⁇ g/100g
- Vitamin E 4.6 mg/100g
- the inventive rose-hip powder contains several vitamins such as vitamin A, vitamin B, vitamin C, vitamin E and vitamin K, as well as several minerals.
- 45g of the inventive powder having an equivalent of 250 mg of vitamin C was administered to healthy volunteers by oral intake with 500 mg of vitamin C given to a control group.
- the concentration of vitamin C in blood was measured at 0, 5, 10, 15, 20 and 25 hours following intake.
- different amounts of the inventive powder were administered to six healthy volunteers and the concentration of vitamin C in blood was measured at 0, 2 and 4 hours following intake.
- PMNs Polymorphonuclear leucocytes
- monocytes Mononuclear leucocytes containing monocytes
- the percentages of monocytes in the mononuclear cell fraction was between 15%-35% and the cell viability was greater than 98%.
- Chemotaxis assay was performed using a modified Boyden chamber technique as previously described in Jensen, P., and Kharazmi, A., Computerassisted image analysis assay of human neutrophil Chemotaxis in vitro. J. Immunol. Methods.144:43. 1991.
- the purified PMNs or mononuclear cells were preincubated with different dilutions of rose-hip extract for 30 min at 37°C.
- the chemotaxis of the cells towards the chemotactic peptide f-Met-Leu-Phe (fMLP) or zymosan activated serum (ZAS) which contains the biologically active chemoattractant C5a were tested.
- the migrated cells were counted by a computer-assisted image analysis system.
- Chemiluminescence assay was used as a measure of oxygen radical generation by activated PMNs. The method was performed as previously described in Kharazmi, A., Hoiby, N., Doring, G., and Valerius, N.H. Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect. Immun. 44:587, 1984. PMNs were preincubated with different concentrations of the inventive rose-hip extract and then stimulated with either fMLP or opsonized zymosan. The oxidative burst response of the activated cells was measured by a 1250 LKB Wallace lumi- nometer. 12
- the volunteers were treated with 45 grams of the inventive rose-hip powder daily for 28 days, and followed for another 28 days during which rose-hip powder was not taken. Before inclusion, all volunteers went through a screening procedure to assure that non of the above mentioned diseases were present. Moreover before inclusion blood samples were taken for C-reactive protein (CRP) measurement to assure that none of the included volunteers suffered from unknown infectious diseases. Furthermore blood potassium, sodium, serum creatinine, alanine-amino transferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, hemoglobin and total cholesterol were also measured before initiation of the treatment. All measurements were performed according to the conventional laboratory routine.
- CRP C-reactive protein
- the uptake of vitamin C present in the inventive powder was as good or even better than uptake of vitamin C when given in tablet form.
- concentrations and kinetics of uptake through gastro-intestinal tract of equivalent of 250 mg vitamin C in the inventive rose-hip powder was similar to 500 mg vitamin C in tablet form.
- the better absorption of vitamin C in rose-hip powder could be due to a larger surface area of rose-hip powders as compared to vitamin C tablets.
- Table 3 shows the chemotaxis results of peripheral blood monocytes incubated with rose-hip extract.
- Rose-hip extract at concentrations of 500 ⁇ g/ml inhibited the chemotaxis of human monocytes by about 80-90%.
- the effect of rose-hip extract on human peripheral blood polymorphonuclear leucocyte (PMN) chemiluminescence response as measured by an LKB luminometer is shown in Table 4.
- Rose-hip extract was prepared by incubating rose-hip powder in MEM for 19 hours at 5°C. After incubation the preparation was centrifuged at 4000 rpm for 10 min and the supernatant was diluted in MEM in appropriate concentrations. The cells were preincubated with different concentrations of rose-hip extract for 30 minutes at 37°C. After preincubation the chemiluminescence response of cells activated by opsonized zymosan was determined. The data are from three experiments performed in duplicate and are presented as percent inhibition of chemiluminescence as compared to control cell response preincubated with buffer alone.
- Vitamin C was used as a control. Vitamin C in crystalline form up to a concentration of 5000 ⁇ g/ml had almost no effect on PMN chemiluminescence when the pH of vitamin C solution was adjusted to the physiological pH 7.2.
- Vitamin E (alpha-tocopherol) was also used as a known anti-oxidant control. Vitamin E at a concentration of over I ⁇ g/ml inhibited chemiluminescence. 18
- the data are presented as mean values from 17 subjects.
- Chemotaxis of peripheral blood polymorphonuclear leucocytes from subjects during and 28 days after cessation of treatment with 45 grams daily intake of rose-hip for 28 days are shown in Table 7.
- the chemotaxis is determined towards the chemotactic peptide fMLP and zymosan activated serum (ZAS) as shown in Table 7.
- the results are given as number of cells migrated.
- the data is shown in Table 7 and figures 3 and 4.
- the mean value of PMN chemotaxis towards the chemotactic peptide fMLP was 123 ⁇ 131 when tested on 28th day of treatment with rose-hip as compared to 315 ⁇ 92 when blood samples were taken 28 days after cessation of treatment with rose-hip (p ⁇ 0.001 ).
- the mean PMN chemotaxis towards zymosan treatment with activated serum (ZAS) which contains the biologically active chemotactic factor C5a was 265 ⁇ 288 as compared to 564 ⁇ 141 when tested 28 days after cessation of treatment with rose-hip (p ⁇ 0.001 ).
- the studies described demonstrate that the rose-hip extract inhibited, in vitro, the chemotaxis and oxidative burst response of the human peripheral blood polymorphonuclear leucocytes, the most important and most abundant inflammatory cells.
- the extract also inhibited/reduced the chemotaxis of monocytes, another important cell type involved in inflammation and in pathogenesis of arthritis. It appears that the inhibition of neutrophil chemotaxis and oxidative burst response by rose-hip extract was not due to vitamin C content of the extract. This is shown by the inability of pH-adjusted vitamin C to inhibit chemiluminescence whereas pH-adjusted extract was still as inhibitory as non-pH-adjusted extract.
- the anti-inflammatory and anti-oxidant properties of rose-hip are important in the inhibition and/or reduction of tissue damage in the inflamed joint. Furthermore, administration of rose-hip to patients with arthritis resulted in alleviating pain and reducing inflammation and other symptoms associated with arthritis.
- rose-hip lowered the level of the acute phase protein C-reactive protein in volunteers with values within normal range, which is below 10 mg/L. This decline was significant and was observed after 10 days of therapy.
- the herbal formulation of this invention is also contemplated to use the herbal formulation of this invention as a therapeutic or prophylactic for non-human mammals, including domestic and farm animals, having arthritis or other T-cell mediated immune disease for which it is desirable to reduce/suppress immune response or alleviate joint pain and stiffness caused by these diseases.
- the formulation can be incorporated into the animal's water source or feed, or it can be administered like a medicament in the form of a capsule, tablet, liquid or the like.
- the drugs presently available for the therapy of arthritis include acetylsalicylic acid such as Aspirin, non-steroid anti-inflammatory drugs such as ibuprofen, methotrexate and naproxen, and glucocorticoid. Control of the symptoms with these drugs requires long term daily treatment. These drugs have a variety of toxic and other side effects, such as gastric erosion and adverse effects on kidneys and liver. Some of these drugs particularly glucocorticoid inhibit the immune response to infections. Therefore, there is a great need for alternative therapies for the management of arthritis which can eliminate the need for traditional drugs and their side effects particularly for prolonged daily use.
- the inventive rose-hip powder possesses these properties, in that it is effective, safe and cheap. As a natural product, it has no side effects. It can be administered by itself alone as capsules, tablets, powder, tea or other preparations. Rose-hips in powder form or as an extract of rose-hip can also be used as an ingredient incorporated into suitable foods or beverages, without special processing requirements, including but 24
- inventive rose-hip powder can also be used in combination with other dietary supplements such as vitamins, minerals and anti-oxidants. Preparations containing rose-hip can be designed for daily consumption as part of therapeutic regimen for arthritis, or as a prophylactic regimen for individuals having a genetic or environmental predisposition to arthritis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31380/99A AU759394B2 (en) | 1998-04-17 | 1999-04-16 | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
EP99913122A EP1071439B1 (en) | 1998-04-17 | 1999-04-16 | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
SI9930915T SI1071439T1 (en) | 1998-04-17 | 1999-04-16 | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
JP2000544338A JP4514333B2 (en) | 1998-04-17 | 1999-04-16 | Rose berry formulation as a natural anti-inflammatory drug to alleviate and reduce symptoms associated with inflammation and arthritis |
NZ501790A NZ501790A (en) | 1998-04-17 | 1999-04-16 | Rose-hip formulations as anti-inflammatory for arthritis |
DE69931907T DE69931907T2 (en) | 1998-04-17 | 1999-04-16 | HAGA BUTTER COMPOSITIONS AS AN ANTI-INFLAMMABLE NATURAL MEDICAMENT TO FACILITATE / REDUCE SYMPTOMS RELATING TO INFLAMMATION AND ARTHRITIS |
CY20061101238T CY1105188T1 (en) | 1998-04-17 | 2006-08-31 | ROSE FORMULATIONS AS NON-INFLAMMATORY ANTI-INFLAMMATORY DRUGS FOR THE RELIEF/MITIGATION OF SYMPTOMS ASSOCIATED WITH INFLAMMATION AND ARTHRITIS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/061,969 US6024960A (en) | 1998-04-17 | 1998-04-17 | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
US09/061,969 | 1998-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999053934A1 true WO1999053934A1 (en) | 1999-10-28 |
Family
ID=22039366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1999/000212 WO1999053934A1 (en) | 1998-04-17 | 1999-04-16 | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
Country Status (12)
Country | Link |
---|---|
US (1) | US6024960A (en) |
EP (1) | EP1071439B1 (en) |
JP (1) | JP4514333B2 (en) |
AT (1) | ATE329605T1 (en) |
AU (1) | AU759394B2 (en) |
CY (1) | CY1105188T1 (en) |
DE (1) | DE69931907T2 (en) |
DK (1) | DK1071439T3 (en) |
ES (1) | ES2267259T3 (en) |
NZ (1) | NZ501790A (en) |
PT (1) | PT1071439E (en) |
WO (1) | WO1999053934A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005513023A (en) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | Use of mono- and diacylglycerol glycosides as anti-inflammatory agents |
WO2007024901A1 (en) * | 2005-08-23 | 2007-03-01 | Access Business Group International Llc | Cytokine modulators and related methods of use |
WO2009080778A2 (en) * | 2007-12-21 | 2009-07-02 | Finzelberg Gmbh & Co. Kg | Preparations with rosehip extracts, and method of producing rosehip extracts |
WO2009131470A1 (en) * | 2008-04-24 | 2009-10-29 | Fonterra Co-Operative Group Limited | Compositions and methods for maintaining bone health or reducing bone loss |
US7838050B2 (en) | 2003-09-12 | 2010-11-23 | Access Business Group International Llc | Cytokine modulators and related method of use |
WO2014005597A1 (en) * | 2012-07-06 | 2014-01-09 | Axellus A/S | Rose hip composition, process for the manufacture of the rose hip composition and said composition for use in a method for the maintenance of flexible joints and decreased inflammation |
US9173912B2 (en) | 2008-05-06 | 2015-11-03 | Finzelberg Gmbh & Co. Kg | Cistus extract containing enriched secondary plant ingredients |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2787320B1 (en) * | 1998-12-17 | 2002-11-29 | Veronique Simon | NOVEL PEELING METHOD AND PREPARATIONS FOR THE IMPLEMENTATION OF THIS METHOD |
US6524609B1 (en) * | 1999-08-18 | 2003-02-25 | Nutri-Vet, Llc | Treating arthritis in animals with dietary supplements |
US6485752B1 (en) * | 2000-10-23 | 2002-11-26 | Otto Torbjorn Hansen | Composition and method for alleviating joint pain and stiffness |
US6979470B2 (en) * | 2001-07-17 | 2005-12-27 | Metaproteomics, Llc | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
EP1418904A4 (en) * | 2001-08-21 | 2007-11-21 | Johnson & Johnson Consumer | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
US20030170327A1 (en) * | 2002-03-05 | 2003-09-11 | Dahl Eva Marie | Vitamin and zinc monomethionine compositions |
US20070003600A1 (en) * | 2003-06-11 | 2007-01-04 | Carolyn Moore | Methods for reducing c-reactive protein |
US7758903B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
US7758902B2 (en) * | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
JP2006316026A (en) * | 2005-05-16 | 2006-11-24 | American Biologics Japan Kk | Rose family plant extract and the like and immune cell-activating agent using the same |
WO2007113007A2 (en) * | 2006-04-04 | 2007-10-11 | Dsm Ip Assets B.V. | Package containing a polyphenol and their uses |
WO2008006582A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases |
EP2049134A2 (en) * | 2006-07-14 | 2009-04-22 | DSMIP Assets B.V. | Compositions comprising rosehip and other active agents for the treatment of inflammatory disorders |
US20110262612A1 (en) * | 2008-04-17 | 2011-10-27 | Goetz Nicolle | Rosehip powder having small particle size |
EP2349281A1 (en) | 2008-10-30 | 2011-08-03 | Hyben Vital Licens ApS | Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition |
DE102009030351A1 (en) | 2009-06-22 | 2010-12-23 | Gelita Ag | Composition for the treatment of degenerative joint diseases |
DK177605B1 (en) | 2010-03-16 | 2013-11-18 | Hyben Vital Licens Aps | Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis |
JP6368229B2 (en) * | 2014-12-02 | 2018-08-01 | 幸三 飯島 | Method for producing vitamin C beverage |
WO2016173995A1 (en) | 2015-04-28 | 2016-11-03 | Hyben Vital Licens Aps | Rose hip product comprising rose hip seeds |
EP3768295A1 (en) * | 2018-03-23 | 2021-01-27 | Arch Biosurgery, Inc. | Sap and peptidomimetic compositions for reducing symptoms of inflammation |
KR102125628B1 (en) * | 2018-12-11 | 2020-06-23 | 주식회사 엘리바이오 | Composition for Cartilage Damage Prevention and Regeneration Containing Rosa Canina Extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
RU2045917C1 (en) * | 1993-07-13 | 1995-10-20 | Всероссийский научно-исследовательский институт консервной и овощесушильной промышленности | Method of processing dog rose berries and line for its realization |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2521275A1 (en) * | 1982-02-08 | 1983-08-12 | Creusot Loire | HEAT EXCHANGER WITH METAL TUBULAR BEAM FOR HIGH TEMPERATURES |
US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
JPH07138151A (en) * | 1993-11-15 | 1995-05-30 | Kanebo Ltd | Soft capsular agent and its production |
US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
-
1998
- 1998-04-17 US US09/061,969 patent/US6024960A/en not_active Expired - Lifetime
-
1999
- 1999-04-16 JP JP2000544338A patent/JP4514333B2/en not_active Expired - Lifetime
- 1999-04-16 AU AU31380/99A patent/AU759394B2/en not_active Expired
- 1999-04-16 PT PT99913122T patent/PT1071439E/en unknown
- 1999-04-16 NZ NZ501790A patent/NZ501790A/en not_active IP Right Cessation
- 1999-04-16 AT AT99913122T patent/ATE329605T1/en active
- 1999-04-16 DK DK99913122T patent/DK1071439T3/en active
- 1999-04-16 EP EP99913122A patent/EP1071439B1/en not_active Expired - Lifetime
- 1999-04-16 WO PCT/DK1999/000212 patent/WO1999053934A1/en active IP Right Grant
- 1999-04-16 DE DE69931907T patent/DE69931907T2/en not_active Expired - Lifetime
- 1999-04-16 ES ES99913122T patent/ES2267259T3/en not_active Expired - Lifetime
-
2006
- 2006-08-31 CY CY20061101238T patent/CY1105188T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
RU2045917C1 (en) * | 1993-07-13 | 1995-10-20 | Всероссийский научно-исследовательский институт консервной и овощесушильной промышленности | Method of processing dog rose berries and line for its realization |
Non-Patent Citations (5)
Title |
---|
"MERCK INDEX, 12th edition, ref. 8422, page 1422", 1996 * |
CHEMICAL ABSTRACTS, vol. 124, no. 24, 10 June 1996, Columbus, Ohio, US; abstract no. 324950, THEN MARIA ET AL.: "Comparative study of evening primrose rose-hip oil (recommendations) and applications" page 1; * |
ERDEM YESILADA ET AL.: "Inhibitory effects of Turkish folk remedies on inflammatory cytokines: interleukin-1alpha, interleukin-1beta and tumor necrosis factor alpha", JOURNAL OF ETHNOPHARMACOLOGY, vol. 58, 1997, pages 59 - 73 * |
K. WINTHER ET AL.: "The anti-inflammatory properties of rose-hip", INFLAMMOPHARMACOLOGY, vol. 7, no. 1, 1999, pages 63 - 68 * |
OLAJ. SZAPPAN, KOZMET., vol. 45(1), 1996, pages 26 - 30 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005513023A (en) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | Use of mono- and diacylglycerol glycosides as anti-inflammatory agents |
JP2010215660A (en) * | 2001-11-21 | 2010-09-30 | Danmarks Jordbrugsforskning | Use of glycoside of mono- and diacylglycerol as anti-inflammatory agent |
JP4716655B2 (en) * | 2001-11-21 | 2011-07-06 | ユニバーシティ・オブ・オーフース | Use of mono- and diacylglycerol glycosides as anti-inflammatory agents |
US7838050B2 (en) | 2003-09-12 | 2010-11-23 | Access Business Group International Llc | Cytokine modulators and related method of use |
KR101245440B1 (en) * | 2003-09-12 | 2013-03-19 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | Cytokine modulators and related method of use |
WO2007024901A1 (en) * | 2005-08-23 | 2007-03-01 | Access Business Group International Llc | Cytokine modulators and related methods of use |
WO2009080778A2 (en) * | 2007-12-21 | 2009-07-02 | Finzelberg Gmbh & Co. Kg | Preparations with rosehip extracts, and method of producing rosehip extracts |
WO2009080778A3 (en) * | 2007-12-21 | 2009-12-17 | Finzelberg Gmbh & Co. Kg | Preparations with rosehip extracts, and method of producing rosehip extracts |
US9937215B2 (en) | 2007-12-21 | 2018-04-10 | Finzelberg Gmbh & Co., Kg | Preparations with rosehip extracts, and method of producing rosehip extracts |
WO2009131470A1 (en) * | 2008-04-24 | 2009-10-29 | Fonterra Co-Operative Group Limited | Compositions and methods for maintaining bone health or reducing bone loss |
US9173912B2 (en) | 2008-05-06 | 2015-11-03 | Finzelberg Gmbh & Co. Kg | Cistus extract containing enriched secondary plant ingredients |
WO2014005597A1 (en) * | 2012-07-06 | 2014-01-09 | Axellus A/S | Rose hip composition, process for the manufacture of the rose hip composition and said composition for use in a method for the maintenance of flexible joints and decreased inflammation |
Also Published As
Publication number | Publication date |
---|---|
DK1071439T3 (en) | 2006-10-16 |
JP4514333B2 (en) | 2010-07-28 |
ATE329605T1 (en) | 2006-07-15 |
EP1071439A1 (en) | 2001-01-31 |
AU3138099A (en) | 1999-11-08 |
DE69931907T2 (en) | 2007-02-22 |
AU759394B2 (en) | 2003-04-17 |
ES2267259T3 (en) | 2007-03-01 |
NZ501790A (en) | 2001-10-26 |
DE69931907D1 (en) | 2006-07-27 |
JP2002512197A (en) | 2002-04-23 |
PT1071439E (en) | 2006-10-31 |
EP1071439B1 (en) | 2006-06-14 |
US6024960A (en) | 2000-02-15 |
CY1105188T1 (en) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1071439B1 (en) | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis | |
Kharazmi et al. | Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo | |
US6262019B1 (en) | Method of treatment of glutathione deficient mammals | |
EP2082738B1 (en) | Use of beta-hydroxy-beta-methylbutyrate to treat asthma | |
US5932624A (en) | Vitamin supplement composition | |
Rondanelli et al. | Ideal food pyramid for patients with rheumatoid arthritis: A narrative review | |
EP2041151B1 (en) | A method of preparing a glycoside of a mono- or diacylglycerol product from a plant material | |
US20060246115A1 (en) | Nutritional products for ameliorating symptoms of rheumatoid arthritis | |
SG191369A1 (en) | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate | |
EP2702996A1 (en) | Anemia-ameliorating composition | |
US6265391B1 (en) | Method for preventing peripheral nerve damage | |
RU2491083C2 (en) | Using phytoecdysone and preparing compositions for treating metabolic syndrome | |
AU777971B2 (en) | Methods and compositions for modulating immune response and for the treatment of inflammatory disease | |
ES2642926T3 (en) | Foods related to the reduction of the level of human cholesterol | |
US8815313B2 (en) | Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis, rheumatoid arthritis and/or osteo-arthritis | |
KR100293890B1 (en) | Food composition for control of body weight and blood sugar prepared by using Dong-A Green Juice and its residue | |
KR101373493B1 (en) | Composition comprising Hizikia fusiformis for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
JP6770726B1 (en) | Preventive or ameliorating agents for metabolic syndrome | |
US20150366938A1 (en) | Nutritional supplement for patients suffering from rheumatic diseases | |
RU2033732C1 (en) | Foodstuff | |
KR0148462B1 (en) | Preparation process of brainactivating soft capsule | |
Khan et al. | Protective effect of nutrition and supplements on COVID-19 management | |
KR20220069174A (en) | Compositions for the prevention or treatment of obesity comprising natural complexes | |
Seshadri et al. | Bioavailability of Spirulina Carotenes in Preschool Children (Dec, 1990) | |
JP2018172346A (en) | Pregnancy support composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 501790 Country of ref document: NZ Ref document number: 31380/99 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999913122 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999913122 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 31380/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999913122 Country of ref document: EP |